EIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion

Journal of Investigative Dermatology

Volumn 135, Issue 5, 2015, Pages 1358-1367

  Khosravi, Shahram ^a   Tam, Kevin J ^a   Ardekani, Gholamreza S ^a   Martinka, Magdalena ^a   McElwee, Kevin J ^a   Ong, Christopher J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GELATINASE A; INITIATION FACTOR 4E; PROTEIN BCL 2; TUMOR MARKER; UVOMORULIN;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CHEMOSENSITIVITY; DISEASE SPECIFIC SURVIVAL; DYSPLASTIC NEVUS; HUMAN; MELANOMA; MELANOMA CELL LINE; METASTATIC MELANOMA; ONCOGENE C MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; CELL MOTION; DISEASE COURSE; FEMALE; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REGRESSION ANALYSIS; SKIN TUMOR; SURVIVAL RATE; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; REGRESSION ANALYSIS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84928423099     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.552     Document Type: Article

References (49)

1. Assouline S, Culjkovic B, Cocolakis E et al. (2009) Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114:257-60
2. Borden KL, Culjkovic-Kraljacic B (2010) Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma 51:1805-15
3. Chen G, Cheng Y, Tang Y et al. (2012) Role of Tip60 in human melanoma cell migration, metastasis, and patient survival. J Invest Dermatol 132:2632-41
4. Dai DL, Martinka M, Li G (2005) Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23:1473-82
5. De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189-99
6. De Benedetti A, Harris AL (1999) eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 31:59-72
7. De Benedetti A, Rhoads RE (1990) Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc Natl Acad Sci USA 87:8212-6
8. Dhawan P, Singh AB, Ellis DL et al. (2002) Constitutive activation of Akt/ protein kinase B in melanoma leads to up-regulation of nuclear factorkappaB and tumor progression. Cancer Res 62:7335-42
9. Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3:362-74
10. Ghosh B, Benyumov AO, Ghosh P et al. (2009) Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol 4:367-77
11. Graff JR, Boghaert ER, De Benedetti A et al. (1995) Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int J Cancer 60:255-63
12. Graff JR, Konicek BW, Lynch RL et al. (2009) eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 69:3866-73
13. Graff JR, Konicek BW, Vincent TM et al. (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117:2638-48
14. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851-7
15. Hariri F, Arguello M, Volpon L et al. (2013) The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-kappaB and is aberrantly regulated in acute myeloid leukemia. Leukemia 27: 2047-55
16. Hsieh AC, Liu Y, Edlind MP et al. (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55-61
17. Hung WC, Tseng WL, Shiea J et al. (2010) Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett 288:156-61
18. Jamerson MH, Johnson MD, Dickson RB (2000) Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene 19:1065-71
19. Johansson N, Ala-aho R, Uitto V et al. (2000) Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci 113:227-35
20. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-64
21. Kentsis A, Topisirovic I, Culjkovic B et al. (2004) Ribavirin suppresses eIF4Emediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA 101:18105-10
22. Khosravi S, Wong RP, Ardekani GS et al. (2014) Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion. Br J Cancer 110:399-408
23. Lazaris-Karatzas A, Montine KS, Sonenberg N (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 345:544-7
24. Li J, Martinka M, Li G (2008) Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 29:1373-9
25. Li Y, Fan S, Koo J et al. (2012) Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther 13:272-80
26. Lin H, Wong RP, Martinka M et al. (2009) Loss of SNF5 expression correlates with poor patient survival in melanoma. Clin Cancer Res 15:6404-11
27. Lu J, Tang Y, Farshidpour M et al. (2013) JWA inhibits melanoma angiogenesis by suppressing ILK signaling and is an independent prognostic biomarker for melanoma. Carcinogenesis 34:2778-88
28. Miller AJ, Mihm MC Jr. (2006) Melanoma. N Engl J Med 355:51-65
29. Minotti G, Menna P, Salvatorelli E et al. (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229
30. Niu Z, Wang J, Muhammad S et al. (2014) Protein expression of eIF4E and integrin alphavbeta6 in colon cancer can predict clinical significance, reveal their correlation and imply possible mechanism of interaction. Cell Biosci 4:23
31. Nogueira V, Sundararajan D, Kwan JM et al. (2012) Akt-dependent Skp2 mRNA translation is required for exiting contact inhibition, oncogenesis, and adipogenesis. EMBO J 31:1134-46
32. Oridate N, Kim HJ, Xu X et al. (2005) Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther 4:318-23
33. Polunovsky VA, Gingras AC, Sonenberg N et al. (2000) Translational control of the antiapoptotic function of Ras. J Biol Chem 275:24776-80
34. Polunovsky VA, Rosenwald IB, Tan AT et al. (1996) Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 16:6573-81
35. Rotte A, Martinka M, Li G (2012) MMP2 expression is a prognostic marker for primary melanoma patients. Cell Oncol (Dordr) 35:207-16
36. Ruggero D, Montanaro L, Ma L et al. (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10:484-6
37. Sato H, Takino T, Okada Y et al. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-5
38. Shankar J, Messenberg A, Chan J et al. (2010) Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res 70:3780-90
39. Simon C, Goepfert H, Boyd D (1998) Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92, 000 type IV collagenase secretion and in vitro invasion. Cancer Res 58:1135-9
40. Sun SY, Rosenberg LM, Wang X et al. (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65:7052-8
41. Tarhini AA, Agarwala SS (2006) Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 19:19-25
42. Vaisanen A, Tuominen H, Kallioinen M et al. (1996) Matrix metalloproteinase- 2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 180:283-9
43. Wendel HG, De Stanchina E, Fridman JS et al. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332-7
44. Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13:781-92
45. Wu M, Liu Y, Di X et al. (2013) EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma. Med Oncol 30:400
46. Yang SX, Hewitt SM, Steinberg SM et al. (2007) Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep 17:281-7
47. Yellen P, Saqcena M, Salloum D et al. (2011) High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 10:3948-56
48. Zhang Z, Chen G, Cheng Y et al. (2011) Prognostic significance of RUNX3 expression in human melanoma. Cancer 117:2719-27
49. Zhu YH, Fu L, Chen L et al. (2013) Downregulation of the novel tumor suppressor DIRAS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Res 73:2298-309